- Home
- BTOG vs APLM Comparison
BTOG vs APLM Comparison
Compare BTOG & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTOG
- APLM
- Stock Information
- Founded
- BTOG 2018
- APLM 2016
- Country
- BTOG Singapore
- APLM United States
- Employees
- BTOG N/A
- APLM N/A
- Industry
- BTOG Finance: Consumer Services
- APLM Blank Checks
- Sector
- BTOG Finance
- APLM Finance
- Exchange
- BTOG Nasdaq
- APLM Nasdaq
- Market Cap
- BTOG 11.0M
- APLM 12.3M
- IPO Year
- BTOG 2019
- APLM N/A
- Fundamental
- Price
- BTOG $0.70
- APLM $9.56
- Analyst Decision
- BTOG
- APLM Strong Buy
- Analyst Count
- BTOG 0
- APLM 2
- Target Price
- BTOG N/A
- APLM $425.00
- AVG Volume (30 Days)
- BTOG 96.5K
- APLM 36.2K
- Earning Date
- BTOG 01-01-0001
- APLM 02-15-2025
- Dividend Yield
- BTOG N/A
- APLM N/A
- EPS Growth
- BTOG N/A
- APLM N/A
- EPS
- BTOG N/A
- APLM N/A
- Revenue
- BTOG $2,888,482.00
- APLM $2,101,000.00
- Revenue This Year
- BTOG N/A
- APLM N/A
- Revenue Next Year
- BTOG N/A
- APLM N/A
- P/E Ratio
- BTOG N/A
- APLM N/A
- Revenue Growth
- BTOG N/A
- APLM 70.54
- 52 Week Low
- BTOG $0.63
- APLM $6.50
- 52 Week High
- BTOG $9.71
- APLM $91.00
- Technical
- Relative Strength Index (RSI)
- BTOG 33.11
- APLM 46.48
- Support Level
- BTOG $0.63
- APLM $9.50
- Resistance Level
- BTOG $0.91
- APLM $10.67
- Average True Range (ATR)
- BTOG 0.10
- APLM 0.92
- MACD
- BTOG -0.00
- APLM -0.04
- Stochastic Oscillator
- BTOG 16.85
- APLM 13.17
About BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.